Fig. 3: Progression-free survival with the addition of pertuzumab or lapatinib to trastuzumab for patients with HER2-positive breast cancer. | npj Breast Cancer

Fig. 3: Progression-free survival with the addition of pertuzumab or lapatinib to trastuzumab for patients with HER2-positive breast cancer.

From: Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis

Fig. 3

Hazard ratios for progression-free survival were extracted from eligible studies and pooled using a random-effects model. Studies here are stratified by disease stage: either early (stage I–II) or advanced (stage III–IV). The size of each box represents the weight of each study in the meta-analysis. The vertical solid line represents the point of equivalence between dual and single HER2 therapy. The vertical dashed and dotted lines represent the points of summary for fixed and random effects models, respectively, and the diamonds represent 95% CI for the summary hazard ratios. Analyses were performed with the R programming language50 and the R package meta51.

Back to article page